Clinical Trial Update: China Post-marketing Surveillance (PMS) Study of Aldurazyme® [Phase 4]

View source ↗

Summary

Phase 4 post-marketing surveillance study of Aldurazyme (laronidase) for Mucopolysaccharidosis I has been completed in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis

Drugs mentioned

• Aldurazyme (Laronidase)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Mucopolysaccharidosis I | Phase 4 | Status: COMPLETED